Summary
The pharmacokinetics of sulfinpyrazone, and the plasma levels of its sulfide and sulfone metabolites, have been determined after a single oral dose (400 mg) and during steady-state conditions (4×200 mg daily for 6 days) in healthy female volunteers. The plasma half-lives of sulfinpyrazone, the sulfone and the sulfide were 3.7, 3.2 and 14.7 h, respectively, during steady-state. After a single dose and during steady state conditions the half-lives of sulfinpyrazone and the sulfone did not differ significantly. The trough plasma levels of the sulfide metabolite exceeded those of the parent compound in four of the six volunteers on the last day of the study. The data suggest that in man the most likely candidate for the prolonged inhibition of platelet aggregation observed after treatment with sulfinpyrazone is its sulfide metabolite, because of its prolonged elimination.
Similar content being viewed by others
References
Kelly WN (1975) Effects of drugs on uric acid in man. Annu Rev Pharmacol 15: 327–350
Anturane Reinfarction Trial Research Group (1980) Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302: 250–256
Anturan Reinfarction Italian Study Group (1982) Sulphinpyrazone in postmyocardial infarction. Lancet 2: 237–242
Margulies EH, White AM, Sherry S (1980) Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. Drugs 20: 179–197
Dieterle W, Faigle JW, Moppart J (1980) New metabolites of sulfinpyrazone in man. Arzneim Forsch 30: 989–993
Kirstein Pedersen A, Jakobsen P, Kampmann JP, Malholm Hansen J (1982) Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone. Clin Pharmacokinet 7: 42–56
Dieterle W, Faigle JW, Mory H, Richter WJ, Theobald W (1975) Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan®) in man. Eur J Clin Pharmacol 9: 135–145
Lecaillon JB, Souppart C, Schoeller J-P, Humbert G, Massias P (1979) Sulfinpyrazone kinetics after intravenous and oral administration. Clin Pharmacol Ther 26: 611–617
Kirstein Pedersen A, Jakobsen P (1981) Sulphinpyrazone metabolism during long-term therapy. Br J Clin Pharmacol 11: 597–603
Buchanan MR, Rosenfeld J, Hirsh J (1978) The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. Thromb Res 13: 883–892
Maguire ED, Pay GF, Wallis RB, White AM (1981) Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan®) in man. Thromb Res 21: 321–327
Bradbrook ID, John VA, Morrison PJ, Rogers HJ, Spector RG (1982) Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. Br J Clin Pharmacol 13: 177–185
Walter E, Staiger Ch, De Vries J, Zimmermann R, Weber E (1981) Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol 19: 353–358
Jakobsen P, Kirstein Pedersen A (1981) Simultaneous determination of sulfinpyrazone and four of its metabolites by high-performance liquid chromatography. J Chromatogr 223: 460–465
Don Brown R, Manno JE (1978) ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 67: 1687–1691
Butler KD, Wallis RB, White AM (1979) A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig. Haemostasis 8: 353–360
Ali M, McDonald JWD (1977) Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med 89: 868–875
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosenkranz, B., Fischer, C., Jakobsen, P. et al. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state. Eur J Clin Pharmacol 24, 231–235 (1983). https://doi.org/10.1007/BF00613823
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613823